ensysce.com (ENSC): שווי פעילות לרווח לפני ריבית, מסים ופחת
The market capitalization trend for Ensysce Biosciences (ENSC) reflects an EV/EBITDA value of 0.00, while patent protection for TAAP and MPAR systems creates significant barriers to entry for competitors. The business is based on developing unique methods for combating opioid addiction, ensuring technological superiority within the industry. Developments regarding gastrointestinal drug safety are constrained by strict regulatory oversight and the high cost of FDA certification.
ensysce.com - פילוחים אנליטיים ומדדי מפתח (ENSC)
Ensysce Biosciences (ENSC) is developing an innovative patent portfolio to combat opioid addiction with the support of US government institutions. The EV/EBITDA multiple on the GURU.Markets chart compares the total enterprise value, including net debt, against operating profit before taxes. This price action allows investors to assess the real value of assets and the capital stability of Ensysce Biosciences (ENSC) amid a high debt load.
